Antisense above resistanceI've been watching rather than buying but this long shot has been showing signs of heating up recently. I might regret that. Two days of double-digit advances.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.015 AUD
−11.92 M AUD
0.00 AUD
851.42 M
About PERCHERON THERAPEUTICS LIMITED
Sector
CEO
James Stuart Garner
Headquarters
Melbourne
Website
Founded
2000
ISIN
AU0000317281
FIGI
BBG000BCF0N8
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PER is 0.088 AUD — it has increased by 1.27% in the past 24 hours. Watch PERCHERON THERAPEUTICS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange PERCHERON THERAPEUTICS LIMITED stocks are traded under the ticker PER.
PER stock hasn't changed in a week, the month change is a −23.81% fall, over the last year PERCHERON THERAPEUTICS LIMITED has showed a 46.67% increase.
We've gathered analysts' opinions on PERCHERON THERAPEUTICS LIMITED future price: according to them, PER price has a max estimate of 0.25 AUD and a min estimate of 0.24 AUD. Watch PER chart and read a more detailed PERCHERON THERAPEUTICS LIMITED stock forecast: see what analysts think of PERCHERON THERAPEUTICS LIMITED and suggest that you do with its stocks.
PER stock is 11.11% volatile and has beta coefficient of −0.28. Track PERCHERON THERAPEUTICS LIMITED stock price on the chart and check out the list of the most volatile stocks — is PERCHERON THERAPEUTICS LIMITED there?
Today PERCHERON THERAPEUTICS LIMITED has the market capitalization of 82.94 M, it has increased by 17.91% over the last week.
Yes, you can track PERCHERON THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
PERCHERON THERAPEUTICS LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
PER earnings for the last half-year are −0.01 AUD per share, whereas the estimation was −0.01 AUD, resulting in a 0.09% surprise. The estimated earnings for the next half-year are −0.01 AUD per share. See more details about PERCHERON THERAPEUTICS LIMITED earnings.
PERCHERON THERAPEUTICS LIMITED revenue for the last half-year amounts to 0.00 AUD, matching the estimated figure, and no changes in revenue are expected for the next half-year.
PER net income for the last half-year is −7.18 M AUD, while the previous report showed −4.74 M AUD of net income which accounts for −51.28% change. Track more PERCHERON THERAPEUTICS LIMITED financial stats to get the full picture.
No, PER doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PER shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PERCHERON THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PERCHERON THERAPEUTICS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PERCHERON THERAPEUTICS LIMITED stock shows the buy signal. See more of PERCHERON THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.